AB Science secures 2.8 million euros via a private placement

On October 17, 2025, AB Science, a company listed on Euronext Paris, announced the successful completion of a private placement raising €2.8 million. This transaction, which does not require approval from the Autorité des Marchés Financiers (AMF), was reserved for a limited number of investors.

The funds raised will support Phase 1 of the AB8939 program for acute myeloid leukemia. This funding will also enable a combination expansion study with Venetoclax, aimed at obtaining strong evidence of efficacy.

The issue included more than 2.4 million new shares, accompanied by warrants, representing 3.52% of the current share capital. This provides AB Science with resources to meet its financing needs until the end of 2025 and beyond.